PLAINSBORO, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a global leader in medical technology, announces the launch of its new CUSA® Clarity ultrasonic tissue ablation platform designed to deliver an innovative, integrated system for enhanced performance and long-lasting surgeon comfort in neurosurgical cases.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...0d2ddd6006
Integra’s CUSA® Clarity was engineered to maximize surgical performance for surgeons, staff and patients through a system that provides power, precision and comfort for complex neurosurgery. The unique CUSA® Clarity system is the only ultrasonic tissue ablation system that combines a tough tissue tip, continuous tissue contact, a precision and ergonomic handpiece, and adaptive power all in one system. These four integrated components provide a greater than 50 percent increase in fibrous tissue removal rate over the CUSA® Excel+ system.
The next generation CUSA® Clarity also features an improved handpiece design with a focus on sustained comfort and precision as well as a sleek new console design with an intuitive touchscreen and CUSA Quick Connect™ cartridge and tubing set to streamline operating room setup and workflow. The system is a scalable platform to support future enhancements.
“This latest innovation in tissue ablation is a result of Integra’s focus on designing and developing an advanced system that meets the surgeons’ needs for enhanced surgical performance, especially for longer and tougher cases like fibrous tissue removal,” says Dan Reuvers, president of the Specialty Surgical Solutions division for Integra. “We’re delighted to bring this new system to a demanding surgical environment that enhances patient care.”
The CUSA® Clarity was developed with extensive feedback from over 150 touchpoints worldwide. CUSA® Clarity is currently available for sale in the U.S. and select EU countries (contact your representative for more information). For U.S. customers, a 98.5% uptime guarantee is available with the addition of Integra’s IntegraLink™ Protection Plus program. CUSA® Clarity was cleared by the U.S. Food and Drug Administration and has obtained CE Mark approval. For more information and further indications for use, visit our website for U.S. customers.
About Integra Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com .
CONTACT: Integra LifeSciences Holdings Corporation Investors Angela Steinway 609-936-2268 angela.steinway@integralife.com Michael Beaulieu 609-750-2827 michael.beaulieu@integralife.com Media Laurene Isip 609-750-7984 laurene.isip@integralife.com
